TY - JOUR
T1 - Novel, broad spectrum anticancer agents containing the tricyclic 5:7:5-fused diimidazodiazepine ring system
AU - Kondaskar, Atul
AU - Kondaskar, Shilpi
AU - Kumar, Raj
AU - Fishbein, James C.
AU - Muvarak, Nidal
AU - Lapidus, Rena G.
AU - Sadowska, Mariola
AU - Edelman, Martin J.
AU - Bol, Guus M.
AU - Vesuna, Farhad
AU - Raman, Venu
AU - Hosmane, Ramachandra S.
PY - 2011/3/10
Y1 - 2011/3/10
N2 - Synthesis of a series of novel, broad spectrum anticancer agents containing the tricyclic 5:7:5-fused diimidazo[4,5-d:4′,5′-f][1,3]diazepine ring system is reported. Compounds 1, 2, 8, 11, and 12 in the series show promising in vitro antitumor activity with low micromolar IC50 values against prostate, lung, breast, and ovarian cancer cell lines. Some notions about structure-activity relationships and a possible mechanism of biological activity are presented. Also presented are preliminary in vivo toxicity studies of 1 using SCID mice.
AB - Synthesis of a series of novel, broad spectrum anticancer agents containing the tricyclic 5:7:5-fused diimidazo[4,5-d:4′,5′-f][1,3]diazepine ring system is reported. Compounds 1, 2, 8, 11, and 12 in the series show promising in vitro antitumor activity with low micromolar IC50 values against prostate, lung, breast, and ovarian cancer cell lines. Some notions about structure-activity relationships and a possible mechanism of biological activity are presented. Also presented are preliminary in vivo toxicity studies of 1 using SCID mice.
KW - 5:7:5-fused tricycles
KW - Synthesis
KW - and ovarian cancers
KW - breast
KW - broad spectrum anticancer activity
KW - diimidazo[4,5-d:4′,5′-f][1,3] diazepine ring system
KW - effects on G1 and S phases of the cell cycle
KW - in vitro screening
KW - lung
KW - preliminary mechanistic studies
KW - prostate
UR - http://www.scopus.com/inward/record.url?scp=79952649904&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000288401500013&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1021/ml100281b
DO - 10.1021/ml100281b
M3 - Article
C2 - 21572541
SN - 1948-5875
VL - 2
SP - 252
EP - 256
JO - ACS Medicinal Chemistry Letters
JF - ACS Medicinal Chemistry Letters
IS - 3
ER -